The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells

Archives of Physiology and Biochemistry

Volumn 114, Issue 3, 2008, Pages 171-177

  Nigro, Julie ^a,b   Potter Perigo, Susan ^c   Ivey, Melanie E ^b,d   De Dios, Stephanie T ^b   Evanko, Stephen P ^c   Wight, Thomas N ^c   Little, Peter J ^b,d  

^a CSIRO   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Glucosamine; Glucose metabolism; Hexosamine pathway; Peroxisome proliferator activated receptor ligands; Proteoglycans

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE; FENOFIBRATE; GLUCOSE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEOGLYCAN; TROGLITAZONE;

ARTICLE; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; HUMAN; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; VASCULAR SMOOTH MUSCLE;

CHROMANS; CULTURE MEDIA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLUCOSE; HUMANS; LIGANDS; MUSCLE, SMOOTH, VASCULAR; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROCETOFEN; PROTEOGLYCANS; THIAZOLIDINEDIONES;

EID: 47549102964     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450802181013     Document Type: Article

References (34)

1. Calabro A, Benavides M, Tammi M, Hascall VC, Midura RJ. 2000a. Microanalysis of enzyme digests of hyaluronan and chondroitin/dermatan sulphate by fluorophore-assisted carbohydrate electrophoresis (FACE). Glycobiology 10:273-81.
2. Calabro A, Hascall VC, Midura RJ. 2000b. Adaptation of FACE methodology for microanalysis of total hyaluronan and chondroitin sulphate composition from cartilage. Glycobiology 10:283-93.
3. Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ. 2005. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25:1903-9.
4. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. 2001. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365-71.
5. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ. 2003. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107:2548-50.
6. de Dios ST, Frontanilla KV, Nigro J, Ballinger ML, Ivey ME, Cawson EA, Little PJ. 2007. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J Diabetes Complications 21:108-17.
7. Diamond GA, Bax L, Kaul S. 2007. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147:578-81.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-89.
9. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, et al. 2002. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277:48051-7.
10. Fruchart JC, Staels B, Duriez P. 2001. PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44:345-52.
11. Gustafsson M, Boren J. 2004. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 15:505-14.
12. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. 2005. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 48:1726-35.
13. Jarvelainen HT, Kinsella MG, Wight TN, Sandell LJ. 1991. Differential expression of small chondroitin/dermatan sulphate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem 266:23274-81.
14. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-61.
15. Kihara S, Ouchi N, Funahashi T, Shinohara E, Tamura R, Yamashita S, Matsuzawa Y. 1998. Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 136:163-8.
16. Komers R, Vrana A. 1998. Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res 47:215-25.
17. Little PJ, Ballinger ML, Osman N. 2007a. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vascular Health Risk Management 3:1-8.
18. Little PJ, Osman N, de Dios ST, Cemerlang N, Ballinger M, Nigro J. 2007b. Anti-proliferative activity of oral anti hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. Cardiovasc Diabetol 6:33.
19. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. 2007. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 27:1159-65.
20. Neve BP, Fruchart J, Staels B. 2000. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 60:1245-50.
21. Neylon CB, Little PJ, Cragoe EJ, Jr., Bobik A. 1990. Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride-sensitive Na(+)- and HCO3(-)-dependent mechanism. Circ Res 67:814-25.
22. Nigro J, Ballinger M, Dilley R, Jennings G, Wight T, Little P. 2004. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces LDL binding. Diabetologia 47:2105-13.
23. Nigro J, Ballinger ML, Osman N, Dart AM, Little PJ. 2005. Anti-atherogenic role of peroxisome proliferator activated receptor ligands. Current Cardiology Reviews 1:89-102.
24. Nigro J, Dilley RJ, Little PJ. 2002. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 162:119-29.
25. Nissen SE, Wolski K. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-71.
26. Plutzky J. 2003. Medicine. PPARs as therapeutic targets: reverse cardiology? Science 302:406-7.
27. Salustri A, Yanagishita M, Hascall VC. 1989. Synthesis and accumulation of hyaluronic acid and proteoglycans in the mouse cumulus cell-oocyte complex during follicle-stimulating hormone-induced mucification. J Biol Chem 264:13840-7.
28. Scatena R, Bottoni P, Martorana GE, Ferrari F, De Sole P, Rossi C, Giardina B. 2004. Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochem Biophys Res Commun 319:967-73.
29. Schonherr E, Jarvelainen HT, Sandell LJ, Wight TN. 1991. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulphate proteoglycan by arterial smooth muscle cells. J Biol Chem 266:17640-7.
30. Tannock LR, Little PJ, Tsoi C, Barrett PHR, Wight TN, Chait A. 2004. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia 47:837-43.
31. Williams KJ, Tabas I. 1995. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551-61.
32. Yanagishita M, Salustri A, Hascall VC. 1989. Specific activity of radiolabeled hexosamines in metabolic labeling experiments. Methods Enzymol 179:435-45.
33. Yao LY, Moody C, Schonherr E, Wight TN, Sandell LJ. 1994. Identification of the proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, in situ hybridization and immunohistochemistry. Matrix Biol 14:213-25.
34. Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Hayashi T, Nakao K. 2001. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50:1093-101.